Medical - Devices
Compare Stocks
4 / 10Stock Comparison
CATX vs RNW vs CWEN vs AGEN
Revenue, margins, valuation, and 5-year total return — side by side.
Renewable Utilities
Renewable Utilities
Biotechnology
CATX vs RNW vs CWEN vs AGEN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Renewable Utilities | Renewable Utilities | Biotechnology |
| Market Cap | $267M | $1.33B | $7.84B | $132M |
| Revenue (TTM) | $576K | $129.66B | $1.43B | $114M |
| Net Income (TTM) | $-114M | $11.97B | $169M | $115K |
| Gross Margin | -150.2% | 77.9% | 50.3% | 35.7% |
| Operating Margin | -184.6% | 48.4% | 12.0% | -17.7% |
| Forward P/E | — | 0.4x | 26.9x | 1.8x |
| Total Debt | $4M | $732.28B | $10.20B | $10M |
| Cash & Equiv. | $62M | $40.42B | $818M | $3M |
CATX vs RNW vs CWEN vs AGEN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 21 | May 26 | Return |
|---|---|---|---|
| Perspective Therape… (CATX) | 100 | 25.7 | -74.3% |
| ReNew Energy Global… (RNW) | 100 | 49.1 | -50.9% |
| Clearway Energy, In… (CWEN) | 100 | 138.9 | +38.9% |
| Agenus Inc. (AGEN) | 100 | 4.7 | -95.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CATX vs RNW vs CWEN vs AGEN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CATX is the clearest fit if your priority is momentum.
- +53.2% vs RNW's -17.7%
RNW carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 19.4%, EPS growth 10.1%, 3Y rev CAGR 17.8%
- 19.4% revenue growth vs CATX's -100.0%
- Lower P/E (0.4x vs 1.8x)
- 1.2% ROA vs CATX's -36.6%, ROIC 4.9% vs 5.2%
CWEN is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 2 yrs, beta 0.54, yield 7.9%
- 237.4% 10Y total return vs RNW's -50.5%
- Lower volatility, beta 0.54, current ratio 1.13x
- Beta 0.54, yield 7.9%, current ratio 1.13x
AGEN lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.4% revenue growth vs CATX's -100.0% | |
| Value | Lower P/E (0.4x vs 1.8x) | |
| Quality / Margins | 11.8% margin vs CATX's -197.3% | |
| Stability / Safety | Beta 0.54 vs AGEN's 2.72 | |
| Dividends | 7.9% yield; 2-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +53.2% vs RNW's -17.7% | |
| Efficiency (ROA) | 1.2% ROA vs CATX's -36.6%, ROIC 4.9% vs 5.2% |
CATX vs RNW vs CWEN vs AGEN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
CATX vs RNW vs CWEN vs AGEN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CWEN leads in 3 of 6 categories
RNW leads 1 • CATX leads 0 • AGEN leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
RNW leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RNW is the larger business by revenue, generating $129.7B annually — 225100.5x CATX's $576,000. CWEN is the more profitable business, keeping 11.8% of every revenue dollar as net income compared to CATX's -197.3%. On growth, RNW holds the edge at +37.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $576,000 | $129.7B | $1.4B | $114M |
| EBITDAEarnings before interest/tax | -$104M | $86.9B | $1.0B | -$10M |
| Net IncomeAfter-tax profit | -$114M | $12.0B | $169M | $115,000 |
| Free Cash FlowCash after capex | -$112M | -$23.8B | $268M | -$159M |
| Gross MarginGross profit ÷ Revenue | -150.2% | +77.9% | +50.3% | +35.7% |
| Operating MarginEBIT ÷ Revenue | -184.6% | +48.4% | +12.0% | -17.7% |
| Net MarginNet income ÷ Revenue | -197.3% | +9.2% | +11.8% | +0.1% |
| FCF MarginFCF ÷ Revenue | -195.2% | -18.4% | +18.8% | -139.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +37.2% | +21.1% | +27.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.2% | +94.8% | -35.3% | +85.3% |
Valuation Metrics
Evenly matched — RNW and AGEN each lead in 2 of 5 comparable metrics.
Valuation Metrics
At 26.9x trailing earnings, CWEN trades at a 43% valuation discount to RNW's 46.9x P/E. On an enterprise value basis, RNW's 11.3x EV/EBITDA is more attractive than CATX's 20.1x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $267M | $1.3B | $7.8B | $132M |
| Enterprise ValueMkt cap + debt − cash | $210M | $8.6B | $17.2B | $140M |
| Trailing P/EPrice ÷ TTM EPS | -2.93x | 46.91x | 26.86x | -1102.94x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 0.40x | — | 1.79x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.59x | — |
| EV / EBITDAEnterprise value multiple | 20.06x | 11.27x | 16.23x | — |
| Price / SalesMarket cap ÷ Revenue | — | 1.30x | 5.48x | 1.16x |
| Price / BookPrice ÷ Book value/share | 0.80x | 1.43x | 0.77x | — |
| Price / FCFMarket cap ÷ FCF | — | — | 21.24x | — |
Profitability & Efficiency
Evenly matched — CATX and RNW each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
RNW delivers a 8.4% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $-43 for CATX. CATX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to RNW's 5.59x. On the Piotroski fundamental quality scale (0–9), AGEN scores 6/9 vs CWEN's 4/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -42.8% | +8.4% | +3.0% | — |
| ROA (TTM)Return on assets | -36.6% | +1.2% | +1.1% | +0.1% |
| ROICReturn on invested capital | +5.2% | +4.9% | +0.9% | — |
| ROCEReturn on capital employed | +5.2% | +6.9% | +1.2% | — |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.01x | 5.59x | 1.72x | — |
| Net DebtTotal debt minus cash | -$58M | $691.9B | $9.4B | $7M |
| Cash & Equiv.Liquid assets | $62M | $40.4B | $818M | $3M |
| Total DebtShort + long-term debt | $4M | $732.3B | $10.2B | $10M |
| Interest CoverageEBIT ÷ Interest expense | -948.77x | 86.76x | 0.55x | 1.11x |
Total Returns (Dividends Reinvested)
CWEN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CWEN five years ago would be worth $17,246 today (with dividends reinvested), compared to $611 for AGEN. Over the past 12 months, CATX leads with a +53.2% total return vs RNW's -17.7%. The 3-year compound annual growth rate (CAGR) favors CWEN at 12.8% vs AGEN's -51.0% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +29.0% | -7.8% | +13.7% | +16.1% |
| 1-Year ReturnPast 12 months | +53.2% | -17.7% | +39.6% | +27.1% |
| 3-Year ReturnCumulative with dividends | -46.2% | +4.4% | +43.5% | -88.2% |
| 5-Year ReturnCumulative with dividends | -59.0% | -45.7% | +72.5% | -93.9% |
| 10-Year ReturnCumulative with dividends | -66.4% | -50.5% | +237.4% | -94.3% |
| CAGR (3Y)Annualised 3-year return | -18.7% | +1.5% | +12.8% | -51.0% |
Risk & Volatility
CWEN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CWEN is the less volatile stock with a 0.54 beta — it tends to amplify market swings less than AGEN's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CWEN currently trades 91.8% from its 52-week high vs AGEN's 51.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.58x | 0.62x | 0.54x | 2.72x |
| 52-Week HighHighest price in past year | $6.16 | $8.24 | $41.54 | $7.34 |
| 52-Week LowLowest price in past year | $1.96 | $4.38 | $27.67 | $2.71 |
| % of 52W HighCurrent price vs 52-week peak | +58.4% | +65.5% | +91.8% | +51.1% |
| RSI (14)Momentum oscillator 0–100 | 39.3 | 64.1 | 45.9 | 48.8 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 734K | 828K | 814K |
Analyst Outlook
CWEN leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: CATX as "Buy", RNW as "Buy", CWEN as "Buy", AGEN as "Buy". Consensus price targets imply 226.4% upside for CATX (target: $12) vs 14.5% for CWEN (target: $44). CWEN is the only dividend payer here at 7.89% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $11.75 | $6.52 | $43.67 | $7.33 |
| # AnalystsCovering analysts | 11 | 6 | 16 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — | +7.9% | — |
| Dividend StreakConsecutive years of raises | 1 | 1 | 2 | 1 |
| Dividend / ShareAnnual DPS | — | — | $3.01 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +0.1% |
CWEN leads in 3 of 6 categories (Total Returns, Risk & Volatility). RNW leads in 1 (Income & Cash Flow). 2 tied.
CATX vs RNW vs CWEN vs AGEN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CATX or RNW or CWEN or AGEN a better buy right now?
For growth investors, ReNew Energy Global Plc (RNW) is the stronger pick with 19.
4% revenue growth year-over-year, versus -100. 0% for Perspective Therapeutics, Inc. (CATX). Clearway Energy, Inc. (CWEN) offers the better valuation at 26. 9x trailing P/E, making it the more compelling value choice. Analysts rate Perspective Therapeutics, Inc. (CATX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CATX or RNW or CWEN or AGEN?
On trailing P/E, Clearway Energy, Inc.
(CWEN) is the cheapest at 26. 9x versus ReNew Energy Global Plc at 46. 9x. On forward P/E, ReNew Energy Global Plc is actually cheaper at 0. 4x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — CATX or RNW or CWEN or AGEN?
Over the past 5 years, Clearway Energy, Inc.
(CWEN) delivered a total return of +72. 5%, compared to -93. 9% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: CWEN returned +237. 4% versus AGEN's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CATX or RNW or CWEN or AGEN?
By beta (market sensitivity over 5 years), Clearway Energy, Inc.
(CWEN) is the lower-risk stock at 0. 54β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 404% more volatile than CWEN relative to the S&P 500. On balance sheet safety, Perspective Therapeutics, Inc. (CATX) carries a lower debt/equity ratio of 1% versus 6% for ReNew Energy Global Plc — giving it more financial flexibility in a downturn.
05Which is growing faster — CATX or RNW or CWEN or AGEN?
By revenue growth (latest reported year), ReNew Energy Global Plc (RNW) is pulling ahead at 19.
4% versus -100. 0% for Perspective Therapeutics, Inc. (CATX). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -44. 7% for Perspective Therapeutics, Inc.. Over a 3-year CAGR, RNW leads at 17. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CATX or RNW or CWEN or AGEN?
Clearway Energy, Inc.
(CWEN) is the more profitable company, earning 11. 8% net margin versus -197. 3% for Perspective Therapeutics, Inc. — meaning it keeps 11. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNW leads at 53. 5% versus -184. 6% for CATX. At the gross margin level — before operating expenses — RNW leads at 91. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CATX or RNW or CWEN or AGEN more undervalued right now?
On forward earnings alone, ReNew Energy Global Plc (RNW) trades at 0.
4x forward P/E versus 1. 8x for Agenus Inc. — 1. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CATX: 226. 4% to $11. 75.
08Which pays a better dividend — CATX or RNW or CWEN or AGEN?
In this comparison, CWEN (7.
9% yield) pays a dividend. CATX, RNW, AGEN do not pay a meaningful dividend and should not be held primarily for income.
09Is CATX or RNW or CWEN or AGEN better for a retirement portfolio?
For long-horizon retirement investors, Clearway Energy, Inc.
(CWEN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 7. 9% yield, +237. 4% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CWEN: +237. 4%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CATX and RNW and CWEN and AGEN?
These companies operate in different sectors (CATX (Healthcare) and RNW (Utilities) and CWEN (Utilities) and AGEN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CATX is a small-cap quality compounder stock; RNW is a small-cap high-growth stock; CWEN is a small-cap income-oriented stock; AGEN is a small-cap quality compounder stock. CWEN pays a dividend while CATX, RNW, AGEN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.